Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société EXELIXIS, INC.
03/25EXELIXIS : Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (c..
BU
03/02EXELIXIS : Announces George A. Scangos, Ph.D. to Retire From Its Board of Direct..
BU
02/26EXELIXIS : Announces Webcasts of Investor Conference Presentations in March
BU
02/25EXELIXIS : 4Q Earnings Snapshot
AQ
02/25EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
02/25EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
02/25EXELIXIS : Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal T..
BU
02/25EXELIXIS : Announces Fourth Quarter and Full Year 2019 Financial Results and Pro..
BU
02/20EXELIXIS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
AQ
02/12EXELIXIS : to Release Fourth Quarter and Full Year 2019 Financial Results on Tue..
BU
02/10EXELIXIS : Announces Encouraging Results for Cabozantinib in Combination With At..
BU
02/06EXELIXIS : Announces Webcasts of Investor Conference Presentations in February
BU
01/29EXELIXIS : Announces Partner Takeda Files New Drug Application in Japan for CABO..
BU
01/27EXELIXIS : Announces Results for Combination of Cabozantinib and Nivolumab With ..
AQ
01/24EXELIXIS : Announces Results for Combination of Cabozantinib and Nivolumab With ..
BU
01/13EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
01/13EXELIXIS : Outlines Key Priorities and Anticipated Milestones for 2020-21, Annou..
AQ
01/12EXELIXIS : Outlines Key Priorities and Anticipated Milestones for 2020-21, Annou..
BU
01/07EXELIXIS : to Present at the 38th Annual J.P. Morgan Healthcare Conference on Ja..
BU
01/07EXELIXIS : Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial o..
BU
2019EXELIXIS : Enters into a Clinical Collaboration for Three Phase 3 Combination Tr..
BU
2019EXELIXIS : Announces Positive Results from IMspire150, the Phase 3 Trial of Atez..
AQ
2019EXELIXIS : Announces Positive Results From IMspire150, the Phase 3 Trial of Atez..
BU
2019EXELIXIS : Announces Webcasts of Investor Conference Presentations in December
BU
2019EXELIXIS : to Present at the Stifel 2019 Healthcare Conference on November 19, 2..
BU
2019EXELIXIS : rsquo; Partner Ipsen Announces Health Canada's Approval of CABOMETYX®..
BU
2019EXELIXIS : rsquo; Collaborator Daiichi Sankyo Announces Positive Results From Ph..
BU
2019EXELIXIS : 3Q Earnings Snapshot
AQ
2019EXELIXIS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2019EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
2019EXELIXIS : Announces Third Quarter 2019 Financial Results and Provides Corporate..
BU
2019EXELIXIS : to Release Third Quarter 2019 Financial Results on Wednesday October ..
AQ
2019EXELIXIS : to Release Third Quarter 2019 Financial Results on Wednesday, October..
BU
2019EXELIXIS : to Present at the 2019 Cantor Global Healthcare Conference on October..
BU
2019EXELIXIS : to Present at the Morgan Stanley 17th Annual Global Healthcare Confer..
BU
2019EXELIXIS : 2Q Earnings Snapshot
AQ
2019EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
2019EXELIXIS : Announces Second Quarter 2019 Financial Results and Provides Corporat..
BU
2019EXELIXIS : to Release Second Quarter 2019 Financial Results on Wednesday, July 3..
BU
2019EXELIXIS : Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With..
BU
2019EXELIXIS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2019EXELIXIS : Announces Webcasts of Investor Conference Presentations in June 2019
BU
2019EXELIXIS, INC. : Material Modification to Rights of Security Holders, Submission..
AQ
2019EXELIXIS : and Iconic Therapeutics Enter into Exclusive Option and License Agree..
BU
2019EXELIXIS : Announces Webcasts of Investor Conference Presentations on May 21, 20..
BU
2019EXELIXIS' : Collaborator Daiichi Sankyo Launches MINNEBRO Tablets in Japan
AQ
2019EXELIXIS : rsquo; Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) T..
BU
2019EXELIXIS : Phase III Trial Launches to Investigate Cabozantinib Plus Nivolumab/I..
AQ
2019EXELIXIS : initiates phase 3 trial of cabozantinib in advanced renal cell carcin..
AQ
2019EXELIXIS : Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Comb..
AQ
2019EXELIXIS : Initiating Phase 3 Pivotal trial of Cabozantinib in Combination with ..
AQ
2019EXELIXIS : 1Q Earnings Snapshot
AQ
2019EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
2019EXELIXIS : Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Comb..
BU
2019EXELIXIS : Announces First Quarter 2019 Financial Results and Provides Corporate..
BU
2019EXELIXIS : Partner Takeda Announces Filing of New Drug Application in Japan for ..
AQ
2019EXELIXIS' : Partner Takeda Announces Filing of New Drug Application in Japan for..
AQ
2019EXELIXIS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2019EXELIXIS : rsquo; Partner Takeda Announces Filing of New Drug Application in Jap..
BU
2019EXELIXIS : to Release First Quarter 2019 Financial Results on Wednesday, May 1, ..
BU
2019EXELIXIS : to Present at the 18th Annual Needham Healthcare Conference on April ..
AQ
2019EXELIXIS : to Present at the 18th Annual Needham Healthcare Conference on April ..
BU
2019EXELIXIS : Announces Webcasts of Investor Conference Presentations in March
BU
2019EXELIXIS : Announces Fourth Quarter and Full Year 2018 Financial Results and Pro..
BU
2019EXELIXIS : to Initiate Phase 1 Clinical Development of XL092, First New Compound..
BU
2019EXELIXIS : to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology D..
BU
2019EXELIXIS : to Release Fourth Quarter and Full Year 2018 Financial Results on Tue..
BU
2019EXELIXIS : Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for ..
BU
2019EXELIXIS : rsquo; Collaborator Daiichi Sankyo Receives Regulatory Approval For M..
BU
2018EXELIXIS : and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib..
BU
2018EXELIXIS : Announces Webcasts of Investor Conference Presentations in November
BU
2018EXELIXIS : rsquo; Partner Ipsen Receives European Commission Approval for CABOME..
BU
2018EXELIXIS : to Present at the Stifel 2018 Healthcare Conference on November 13, 2..
BU
2018EXELIXIS : Announces Third Quarter 2018 Financial Results and Provides Corporate..
BU
2018EXELIXIS : Announces Results from the Dose-Escalation Stage of the Phase 1b COSM..
BU
1  2  3  4  5  6  7Next
Upcoming event on EXELIXIS, INC.